Figure 4.

Change in intrahepatic triglyceride (IHTG) content. Intrahepatic triglyceride content for all subjects with increases in alanine aminotransferase >2× the upper limit of normal (ULN) (n = 15). I, the highest measurement performed; filled circle, measurements performed between Weeks 24 and 31; filled triangle, measurement performed after Week 35; filled square, measurements performed at early termination in Weeks 7 and 15; open square, measurement in a patient from the placebo group who refused follow-up because of claustrophobia; II, the lowest value measured during follow-up between Weeks 50 and 90. Horizontal dotted line represents the upper limit of normal of 5.6% for intrahepatic triglyceride content. The median absolute change from highest intrahepatic triglyceride content to lowest intrahepatic triglyceride content at follow-up was −17.7% (−6.4 to −38.0; n= 12, P= 0.0005).